Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Erratum

doi:10.5114/pg.2023.129421

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Rada naukowa Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac

Panel Redakcyjny

Zgłaszanie i recenzowanie prac online

NOWOŚĆ

Portal dla gastroenterologów!

www.egastroenterologia.pl

Wyszukiwanie

Zasady redakcyjne

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Otwarty dostęp

2/2023
vol. 18

Poleć ten artykuł:

Wyślij znajomemu

Skopiuj link:

Udostępnij:

streszczenie artykułu:

List do Redakcji

Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Erratum

Gastroenterology Rev 2023; 18 (2): 224

DOI: https://doi.org/10.5114/pg.2023.129421

Data publikacji online: 2023/07/27

Pełna treść artykułu Pobierz cytowanie

Metryki PlumX:

The authors have advised that there is an error in the article “Guidelines for the management of ulcerative colitis. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterolog” paper.
Page 10. The sentences “Vedolizumab is administered first in induction therapy by intravenous infusion (300 mg in a 0–2–6 week regimen), and then in maintenance therapy by intravenous infusion (300 mg every 8 weeks). An additional dose of the drug is allowable at week 10 after treatment initiation if no discernible clinical benefit has been obtained after 3 induction doses. Also maintenance therapy dosing can be intensified, by administering 300 mg intravenously every 4 weeks, depending on the clinical presentation.” should read “Vedolizumab is administered first in induction therapy by intravenous infusion (300 mg in a 0–2–6 week regimen), and then in maintenance therapy by intravenous infusion (300 mg every 8 weeks). The maintenance therapy dosing can be intensified, by administering 300 mg intravenously every 4 weeks, depending on the clinical presentation.”
The article has since been corrected online.

Reference

Pełna treść artykułu...